{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:58:53Z","timestamp":1785322733855,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013003","name":"University of Cagliari","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012457","name":"American Ornithological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018429","name":"Istituto Europeo di Oncologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.critrevonc.2025.104709","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T03:23:28Z","timestamp":1743218608000},"page":"104709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel"],"prefix":"10.1016","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-0224","authenticated-orcid":false,"given":"Paolo","family":"Bossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Ghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Ghiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Morbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Rampinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Deborah","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104709_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/ijo.2023.5550","article-title":"Modulation of PD-L1 expression by standard therapy in head and neck cancer cell lines and exosomes","volume":"63","author":"Affolter","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib2","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.3390\/cancers14163894","article-title":"Oligometastatic head and neck cancer: Challenges and perspectives","volume":"14","author":"Bahig","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104709_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.acr.2021.05.002","article-title":"Head and neck cancer: Current challenges and future perspectives","volume":"152","author":"Bhat","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104709_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1348045","article-title":"Real-world use of first-line pembrolizumab +\u2009platinum +\u2009taxane combination regimens in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"14","author":"Black","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3389\/fonc.2019.00926","article-title":"Quality assessment in supportive care in head and neck cancer","volume":"9","author":"Bonomo","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib6","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/annonc\/mdx439","article-title":"A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"28","author":"Bossi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib7","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104709_bib8","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104709_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2025.104709_bib10","first-page":"S295","article-title":"Taxane-based treatment in recurrent\/metastatic head and neck cancer","volume":"33","author":"Dzienis","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41379-020-00710-9","article-title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer","volume":"34","author":"Emancipator","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib12","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1200\/JCO.2024.42.16_suppl.6003","article-title":"Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent\/metastatic (R\/M) HPV16-positive oropharyngeal cancer (OPC)","volume":"42","author":"Even","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ijrobp.2017.12.300","article-title":"Two-year update from CheckMate 141: Outcomes with nivolumab (Nivo) vs investigator\u2019s choice (IC) in recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN) in the overall population and PD-L1 subgroups","volume":"100","author":"Ferris","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104709_bib14","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104709_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101426","article-title":"Therapeutic approaches for the treatment of head and neck squamous cell carcinoma\u2014An update on clinical trials","volume":"21","author":"Goel","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib16","first-page":"477","article-title":"Concordance between three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) in a multicenter study","volume":"12","author":"Guerini Rocco","year":"2022","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104709_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib18","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamaoto.2020.3496","article-title":"Patterns of multidisciplinary care of head and neck squamous cell carcinoma in Medicare patients","volume":"146","author":"Hansen","year":"2020","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.critrevonc.2025.104709_bib19","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2015.62.1086","article-title":"Genetic landscape of human papillomavirus\u2013associated head and neck cancer and comparison to tobacco-related tumors","volume":"33","author":"Hayes","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib20","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3390\/cancers13102371","article-title":"Recurrent\/metastatic squamous cell carcinoma of the head and neck: A big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies","volume":"13","author":"Ionna","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104709_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2025.104709_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/PAI.0000000000000941","article-title":"Intrapatient tumor heterogeneity in IHC interpretation using PD-L1 IHC 22C3 pharmDx","volume":"29","author":"Kalpakoff","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib23","article-title":"PD-L1 expression in head and neck cancer tissue specimens decreases with time","volume":"237","author":"Karpathiou","year":"2022","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.critrevonc.2025.104709_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104709_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104709_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102984","article-title":"Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma\u2014A systematic review and meta-analysis","volume":"153","author":"Lau","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/0194599820912029","article-title":"Supportive care needs of patients with head and neck cancer referred to palliative medicine","volume":"163","author":"Lin","year":"2020","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.critrevonc.2025.104709_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cncy.22501","article-title":"Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma","volume":"130","author":"Liu","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106768","article-title":"De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control \u201calways\u201d matter?","volume":"152","author":"Lorini","year":"2024","journal-title":"Oral. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104709_bib30","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/cancers13020338","article-title":"Recent advances and future directions in clinical management of head and neck squamous cell carcinoma","volume":"13","author":"Muzaffar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104709_bib32","unstructured":"National Comprehensive Cancer Network: NCCN Practice Guidelines in Oncology: Head and Neck Cancers, 2016. <\u3008http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\u3009."},{"key":"10.1016\/j.critrevonc.2025.104709_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106183","article-title":"Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck","volume":"135","author":"Park","year":"2022","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e14534","article-title":"Toxicities in immunotherapy: Can they predict response?","volume":"34","author":"Prior","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent\/metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104709_bib36","first-page":"4315","article-title":"Cancer stem cells of head and neck squamous cell carcinoma: Distance towards clinical application; A systematic review of literature","volume":"13","author":"Sun","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104709_bib37","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"42","key":"10.1016\/j.critrevonc.2025.104709_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/EDBK_350442","article-title":"Current therapy for metastatic head and neck cancer: Evidence, opportunities, and challenges","author":"Wise-Draper","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2025.104709_bib39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy versus chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: A multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol."}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2025.104753","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:29:32Z","timestamp":1762352972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S1040842825000976"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104709","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104709"}}